Breast Surgeons Live
Back to Activities List
Session Title:
Genetic Testing and Management of Results
Date & Time:
December 14, 2022, 7:00 PM ET
CME Deadline:
December 14, 2023
Log in to access members-only content.
Target Audience:
Physicians
Objectives:
At the conclusion of this course, participants should be able to:
- Understand the current controversies in genetics with relationship to multi-gene testing
- Provide pre- and post-test counseling for genetic testing
- Understand how to interpret and explain genetic test results, including variants of undetermined significance
- Manage patients without a genetic mutation based on other breast cancer risk factors
- Discuss advanced imaging modalities for breast cancer screening in high-risk populations and develop an algorithm for their use
Description:
Panel genetic testing for pathogenic mutations in breast cancer predisposition genes is recommended to be available for patients recently diagnosed with breast cancer. This panel will discuss indications for genetic testing and influence of results on surgical and systemic treatment.
Agenda:
Welcome and Introduction
Jennifer Plichta, MD, MS, FACS
Indications for Genetic Testing, What Panels Are Available, and When to Re-test Patients
Karlena Lara-Otero PhD, MS, CGC
Surgical Management Recommendations for BRCA, PALB2, CHEK2 and Other Mutations
Kevin Hughes, MD, FACS
How Genetic Testing Results Influences Systemic Therapy and Radiation Therapy
Siddhartha Yadav, MBBS, MD
Q&A
Faculty:
Moderator—Jennifer Plichta, MD, MS, FACS
Duke University Medical Center
Durham, NC
Kevin Hughes, MD, FACS
Medical University of South Carolina
Charleston, SC
Karlena Lara-Otero PhD, MS, CGC
Stanford Medicine | Health Care
Stanford, CA
Siddhartha Yadav, MBBS, MD
Mayo Clinic
Rochester, MN
References:
- American Society of Breast Surgeons Guideline on Genetic Testing for Breast Cancer Patients.
- NCCN guidelines Version 1.2023: Genetic/Familial High-Risk assessment: Breast, Ovarian, and Pancreatic.
- Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . Kurian, A. W., Griffith, K. A., Hamilton, A. S., Ward, K. C., Morrow, M., Katz, S. J., & Jagsi, R. (2017). Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . JAMA, 317(5), 531–534.
- Patient communication of cancer genetic test results in a diverse population. Ricker, C. N., Koff, R. B., Qu, C., Culver, J., Sturgeon, D., Kingham, K. E., … Idos, G. E. (2018). Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 8(1), 85–94.
- Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Trosman, J. R., Weldon, C. B., Douglas, M. P., Kurian, A. W., Kelley, R. K., Deverka, P. A., & Phillips, K. A. (2017). Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Journal of the National Comprehensive Cancer Network : JNCCN, 15(2), 219–228.
- Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Kurian, A. W., Li, Y., Hamilton, A. S., Ward, K. C., Hawley, S. T., Morrow, M., … Katz, S. J. (2017). Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Journal of Clinical Oncology , JCO2016716480-?
- Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2017). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics.
- High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling. Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N. J Genet Couns. 2015 Nov 4. [Epub ahead of print] PMID: 26531312
- Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Lerner-Ellis J, Khalouei S, Sopik V, Narod SA. Expert Rev Anticancer Ther. 2015 Nov;15(11):1315-26. doi:10.1586/14737140.2015.1090879. Epub 2015 Nov 2.
- Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis.Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J.Ann Oncol. 2015 Dec 8. pii: mdv590. [Epub ahead of print] Review.PMID: 26646754
- Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Brentnall AR, Harkness EF, Astley SM, Donnelly LS, Stavrinos P, Sampson S, Fox L, Sergeant JC, Harvie MN, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Howell A, Cuzick J, Evans DG. Breast Cancer Res. 2015 Dec 1;17(1):147. doi: 10.1186/s13058-015-0653-5. PMID: 26627479
Disclosures:
Use the link below to view disclosure information for all individuals and groups involved in the planning, implementation, and evaluation of this educational activity.
View Disclosure Information (pdf)
View Disclosure Information (pdf)
